|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||90.00 - 90.00|
|52 Week Range||65.00 - 91.50|
|PE Ratio (TTM)||23.33|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
If successful, the drug should be safer, work better and be more convenient to take than current options, the company said.
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.
Up more than 47% over the past year, AbbVie (ABBV) has been a great stock. Today, Scala upgraded AbbVie to Outperform and raised his price target from $95 a share to $105 a share, calling the company the industry’s "3rd best growth prospect with the 3rd lowest PE multiple.” We raised estimates in 2020-22 and now forecast ABBV sales and EPS CAGRs of 7% and 12% (vs. 6% and 10% previously) during 2016-22, placing it third best in sales and profit growth in the industry. Scala says AbbVie made a good showing last week at Cowen’s annual therapeutics conference.
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
In today's episode, we offer up some insights into the risks and rewards associated with owning pharmaceutical dividend darlings Johnson & Johnson, AbbVie, and Pfizer.
The FDA has already approved cheaper biosimilar versions of three drugs that will cost Americans a combined $21 billion this year. Here's why you probably won't be able to buy any of them for a long time.